Claudia Tosti, Valentina Cappelli and Vincenzo De Leo*
Background: Insulin resistance is characteristic of patients with metabolic syndrome and it’s more pronounced in overweight patients. In the long term there may be cardiovascular and pressor consequences. Lifestyle and diet changes may partly improve these aspects. The use of insulin-sensitizing drugs such as metformin gives good results, although side effects limit its use. Recently, new molecules exerting a similar effect without side effects have been put on the market, such as the d-chiro-inositol, a new insulin-sensitizing molecule. Have been proposed various associations between inositol and ingredients able to potentiate its therapeutic effect.
Materials and methods: This was a prospective study. 40 women were recruited aged >40 years in perimenopause with metabolic syndrome with insulin resistance, altered lipid parameters and with a BMI>25. Were evaluated: BMI, insulin levels and fasting plasma glucose, lipid profile (total cholesterol, HDL, triglycerides). The patients were divided into 2 groups: group A treated with a new oral product containing d-chiro-inositol 100 mg, monacolin-K 3 mg, bergamot extract 250 mg, methylfolate 200 mcg and natural vitamin K2 45 mcg (Mesix®) in tablets for 6 months, one tablet per day. Group B not treated and followed for 6 months.
Results:The results demonstrated a significant reduction in the levels of almost all parameters in the group treated with this new supplement, without any side effect.
Conclusions:This innovative natural supplement, thanks to the synergy of action of its components, can be a new effective alternative in prevention and treatment of metabolic syndrome in perimenopausal women.
PDFShare this article
Journal of Metabolic Syndrome received 48 citations as per Google Scholar report
